Avalo Therapeutics, Inc.
Q2 2026 13F Holders
Symbol
AVTX
CUSIP
05338F306
Type
Equity
Class
COM NEW
Num filers
127
Total reported value, excl. options
$1.31B
Compare 2026 Q2 to
2026 Q3
2026 Q1
2025 Q4
2025 Q3
2025 Q2
2025 Q1
2024 Q4
2024 Q3
2024 Q2
2024 Q1
2023 Q4
Excl. options
Options only
All
Manager
Report Date
Value ($000)
Shares
Option Type